The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents
Abstract
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day. However, steady-state plasma fluvoxamine [corrected] concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents; thus, the maximum fluvoxamine dosage recommended for children is 200 mg/day. Fluvoxamine (50 to 300 mg/day) for 8 to 16 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) [measured across multiple assessment scales] compared with placebo in a well controlled trial in paediatric patients (n = 120) or from baseline in noncomparative trials in adolescent (n = 20) or paediatric (n = 16) patients. Improvements with fluvoxamine (up to 200 mg/day) were observed for up to 1 year in 98 patients with OCD in a noncomparative trial. The drug (up to 250 or 300 mg/day) also improved symptoms of anxiety compared with placebo in an 8-week well controlled trial in 128 paediatric patients with social phobia, separation anxiety disorder or generalised anxiety disorder (GAD). Fluvoxamine (50 to 300 mg/day) appears to be well tolerated in paediatric patients, with most adverse events with the drug (except abdominal discomfort, which occurred more often in patients receiving fluvoxamine) occurring with a similar incidence to those with placebo. The most common adverse events involved the central nervous system or gastrointestinal system. Most adverse events reported by paediatric patients with OCD were similar to those reported by adults. In conclusion, fluvoxamine is generally well tolerated and has demonstrated short-term efficacy compared with placebo in the treatment of OCD, and social phobia, separation anxiety disorder or GAD in well controlled trials in paediatric patients. Reductions in symptoms of anxiety with fluvoxamine have been observed for up to 1 year in children and adolescents with OCD. However, there are currently no comparative trials of fluvoxamine with other pharmacological agents. In the absence of such trials, current consensus opinion recommends that when pharmacotherapy is indicated, fluvoxamine, like other SSRIs, can be used as first-line treatment for anxiety disorders, particularly OCD, in paediatric patients. However, direct comparisons are required to assess the relative efficacy and tolerability of pharmacological agents in order to make firm recommendations for the treatment of anxiety disorders in this patient group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Benfield, P., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632040-00002 · Cited by 494
March, J. S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E. H., Cutler, N. R., Dominguez, R., Ferguson, J., Muller, B., et al. (1998) · JAMA · doi:10.1001/jama.280.20.1752 · Cited by 469
Clomipramine Treatment of Childhood Obsessive-Compulsive Disorder: A Double-blind Controlled Study
Flament, M. F. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330057007 · Cited by 466
RIDDLE, M. A., REEVE, E. A., YARYURA-TOBIAS, J. A., YANG, H. M., CLAGHORN, J. L., GAFFNEY, G., GREIST, J. H., HOLLAND, D., MCCONVILLE, B. J., PIGOTT, T., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00017 · Cited by 402
Heel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198224030-00001 · Cited by 384
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
DEVEAUGH-GEISS, J., MOROZ, G., BIEDERMAN, J., CANTWELL, D., FONTAINE, R., GREIST, J. H., REICHLER, R., KATZ, R., & LANDAU, P. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00008 · Cited by 349
RIDDLE, M. A., SCAHILL, L., KING, R. A., HARDIN, M. T., ANDERSON, G. M., ORT, S. I., SMITH, J. C., LECKMAN, J. F., & COHEN, D. J. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199211000-00011 · Cited by 345
Research works printed but not linked: 13
- Benfield, 1986, Drugs, 32, 482
- Richelson, 1984, J Pharmacol Exp Ther, 230, 94
- Horton, 1994, Can J Physiol Pharmacol, 72, 442
- Laird, 1993, J Clin Psychiatry, 54, 224
- ZumBrunnen, 2001, Clin Pharmacol Ther, 69, 82
- Vandel, 1997, Therapie, 52, 74
- Xu, 1996, Chung-Kuo Yao Li Hsueh Pao [Acta Pharmacol Sin], 17, 399
- Spina, 1993, Int J Clin Pharmacol Res, 13, 167
- DeVane, 1997, Am J Psychiatry, 154, 1317
- van den Brekel, 1994, Can Med Assoc J, 151, 1289
- Macher, 1999, Hamberg, II, 108
- 1997, J Clin Psychiatry, 58, 1
- DeVane, 1996, J Clin Psychiatry, 57, 55
Cited by
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
The risks versus the benefits of pharmacological intervention in social anxiety disorder in children
Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461763 · Cited by 2
Metadata
- Authors
- Cheer, S. M., & Figgitt, D. P.
- Corresponding author
- Cheer, Susan M.
- ORCID
- Figgitt, David P.
- Venue
- Paediatric Drugs
- Published
- 2001
- Volume
- 3
- Issue
- 10
- Pages
- 763-781
- ISSN
- 1174-5878 (ISSN-L)
- OpenAlex
- W2041245802
- Cited by
- 15
- References
- 96
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2016: 2 · 2013: 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pediatric Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- fluvoxamine, selective serotonin reuptake inhibitors, obsessive-compulsive disorder, social anxiety disorder, separation anxiety disorder, generalized anxiety disorder, plasma drug concentration, adverse events, drug tolerability, first-line therapy, dosing recommendations, long-term treatment outcomes, placebo comparison, central nervous system adverse events
- MeSH terms
- Adolescent, Anxiety, Separation, Child, Drug Interactions, Humans, Obsessive-Compulsive Disorder, Phobic Disorders, Anti-Anxiety Agents, Fluvoxamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents. https://app.cochat.ai/papers/10.2165/00128072-200103100-00004
- The paper
- Cheer, S. M., & Figgitt, D. P. (2001). Fluvoxamine: A Review of its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents. Paediatric Drugs. https://doi.org/10.2165/00128072-200103100-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.